Target
PDL-1
6 abstracts
Abstract
Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.Org: Centre Léon Bérard, Centre Paul Strauss, CH Bretagne, Centre Henri Becquerel, Clinique des Ormeaux,
Abstract
Effect of placental circulating T cells expressing CD16 on multiple hematological and solid tumor cancers through combination with various monoclonal antibodies.Org: Celularity Inc.,
Abstract
Immune checkpoint inhibitors in advanced malignant peritoneal mesothelioma: Clinical insights, immunopathologic profiling, and prognostic implications from a single-center study.Org: Department of General and Oncological Surgery,
Abstract
PD-1 checkpoint inhibitors related immune-mediated hepatitis in colon cancer: A systematic review and meta-analysis.Org: New York Medical College - Saint Michael's Medical Center, Landmark Medical Center,
Abstract
Efficacy and safety of second-line immunotherapy in patients with advanced non-small cell lung cancer.Org: Hospital Juan Ramón Jiménez, Hospital Juan Ramon Jimenez, Aodo Asociación Onubense Para,
Abstract
Weight loss (WL) as a predictive factor for immune oncology (IO).Org: University of Arkansas for Medical Sciences (UAMS), UAMS Clinical Practice,